|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
179,400,000 |
Market
Cap: |
199.13(M) |
Last
Volume: |
686,440 |
Avg
Vol: |
2,244,045 |
52
Week Range: |
$0.449 - $1.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
27,398 |
133,163 |
206,518 |
439,773 |
Total Sell Value |
$35,069 |
$211,063 |
$253,972 |
$733,404 |
Total People Sold |
3 |
5 |
5 |
9 |
Total Sell Transactions |
3 |
8 |
14 |
31 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-01-19 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
18,999 |
|
- |
|
Robin Howard W |
President & CEO |
|
2016-01-19 |
4 |
AS |
$14.12 |
$941,338 |
D/D |
(66,667) |
10,000 |
|
- |
|
Robin Howard W |
President & CEO |
|
2016-01-19 |
4 |
OE |
$6.46 |
$430,669 |
D/D |
66,667 |
76,667 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2016-01-19 |
4 |
AS |
$14.12 |
$164,738 |
D/D |
(11,667) |
5,251 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2016-01-19 |
4 |
OE |
$6.46 |
$75,369 |
D/D |
11,667 |
16,918 |
|
- |
|
Kuebler Christopher A |
Director |
|
2015-12-04 |
4 |
S |
$15.82 |
$237,300 |
D/D |
(15,000) |
20,000 |
|
- |
|
Kuebler Christopher A |
Director |
|
2015-12-04 |
4 |
OE |
$5.15 |
$77,250 |
D/D |
15,000 |
35,000 |
|
- |
|
Robin Howard W |
President & CEO |
|
2015-12-03 |
4 |
AS |
$15.87 |
$1,983,766 |
D/D |
(125,001) |
10,000 |
|
- |
|
Robin Howard W |
President & CEO |
|
2015-12-03 |
4 |
OE |
$6.46 |
$837,840 |
D/D |
125,001 |
135,001 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2015-12-03 |
4 |
AS |
$15.87 |
$714,166 |
D/D |
(45,001) |
5,251 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2015-12-03 |
4 |
OE |
$6.46 |
$308,040 |
D/D |
45,001 |
50,252 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2015-12-03 |
4 |
AS |
$15.87 |
$238,050 |
D/D |
(15,000) |
3,999 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2015-12-03 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
18,999 |
|
- |
|
Wang Susan |
Director |
|
2015-11-20 |
4 |
AS |
$15.02 |
$743,490 |
D/D |
(49,500) |
20,000 |
|
- |
|
Wang Susan |
Director |
|
2015-11-20 |
4 |
OE |
$5.14 |
$418,430 |
D/D |
49,500 |
60,000 |
|
- |
|
Wang Susan |
Director |
|
2015-11-19 |
4 |
AS |
$15.02 |
$227,223 |
D/D |
(15,128) |
20,000 |
|
- |
|
Wang Susan |
Director |
|
2015-11-19 |
4 |
OE |
$5.14 |
$77,758 |
D/D |
15,128 |
35,128 |
|
- |
|
Wang Susan |
Director |
|
2015-11-18 |
4 |
AS |
$15.00 |
$305,580 |
D/D |
(20,372) |
20,000 |
|
- |
|
Wang Susan |
Director |
|
2015-11-18 |
4 |
OE |
$5.14 |
$153,162 |
D/D |
20,372 |
25,372 |
|
- |
|
Robin Howard W |
President & CEO |
|
2015-11-11 |
4 |
AS |
$13.52 |
$1,690,000 |
D/D |
(125,000) |
10,000 |
|
- |
|
Robin Howard W |
President & CEO |
|
2015-11-11 |
4 |
OE |
$6.46 |
$837,833 |
D/D |
125,000 |
135,000 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2015-11-11 |
4 |
AS |
$13.52 |
$608,400 |
D/D |
(45,000) |
4,751 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2015-11-11 |
4 |
OE |
$6.46 |
$308,033 |
D/D |
45,000 |
49,751 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2015-11-11 |
4 |
AS |
$13.52 |
$202,800 |
D/D |
(15,000) |
3,499 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2015-11-11 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
18,499 |
|
- |
|
709 Records found
|
|
Page 26 of 29 |
|
|